Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Isosorbide mononitrate" patented technology

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease).

A flotation reagent for inhibiting calcite in fluorite-barite intergrowth ore

ActiveCN118341571BParaffin waxCalcite
The present application belongs to the technical field of mineral processing. The present application provides a flotation reagent for inhibiting calcite in fluorite-barite intergrowth ore, which comprises a collector and an inhibitor; the collector comprises at least one of sodium oleate and oxidized paraffin soap; the inhibitor comprises 5-mononitrate isosorbide and water glass in a weight ratio of 4-5:1. The present application also provides a corresponding flotation method, which comprises the steps of: preparing fluorite-barite intergrowth ore containing calcite into ore slurry, and then adding the collector and the inhibitor described in claim 1 or 2 to the obtained ore slurry for flotation. The present application can effectively inhibit calcite during the flotation of fluorite-barite intergrowth ore and improve the fluorite recovery rate, and the obtained CaF2 recovery rate is as high as 95% or more; the flotation reagent used in the present application has a small amount of use and low flotation cost.
Owner:重庆市地质矿产测试中心

Docosahexaenoic acid ester for cardiovascular disease

UndeterminedPK141412AAlcoholAuricular fibrillation
The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula: 1 pantthenol of the following formula:2 and inositol of the following formula:3 or with isosorbide of the following formula:4 or isosorbide mononitrate of the following formula:5 It also relates to a method of preparation of same, a pharmaceutical composition same and the of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.
Owner:PIERRE FABRE MEDICAMENT SAS

Class of salt compounds of isosorbide mononitrate derivatives and use thereof

PCT designated stageWO2026061429A1Nervous disorderOrganic chemistryNR1 NMDA receptorPharmaceutical drug
The present invention belongs to the field of pharmaceuticals. Disclosed in the present invention are a class of salt compounds of isosorbide mononitrate derivatives and the use thereof. Salts formed by the isosorbide mononitrate derivatives of the present invention and D-cycloserine exhibit dual activities as a nitric oxide donor and a partial NMDA receptor agonist. The present invention further relates to the use of the salts formed by the isosorbide mononitrate derivatives and D-cycloserine in a drug for treating cerebral stroke or the recovery period of cerebral stroke.
Owner:NEURODAWN PHARM CO LTD

Sustained-release mononitrate isosorbide tablet and preparation method thereof

The application belongs to the technical field of direct compression of pharmaceutical preparations, and particularly relates to a sustained-release isosorbide mononitrate tablet and a preparation method thereof. The sustained-release tablet is composed of a sustained-release tablet core and a coating layer. After isosorbide mononitrate, hydroxypropyl cellulose, palm wax, silicon dioxide, microcrystalline cellulose-lactose and talc powder are mixed, the powder is directly compressed into a tablet. The obtained tablet is coated into a film-coated tablet by using a moisture-proof coating material (AMB). The powder direct compression technology is adopted, so that the technical complexity is greatly reduced, and the wet heat unit operation is avoided. The preparation process is simple, and the quality is stable.
Owner:SHANDONG NEW TIME PHARMA CO LTD

Mononitrate isosorbide orally dissolving film formulation and method of preparation thereof

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a mononitrate isosorbide oral dissolving film and a preparation method thereof. The mononitrate isosorbide oral dissolving film preparation is composed of a drug-containing layer and isolation layers which are compounded on the upper and lower surfaces of the drug-containing layer. The drug-containing layer comprises the following raw materials in percentage by mass: cyclodextrin-encapsulated mononitrate isosorbide 10-60%, film-forming material 20-80%, plasticizer 0-20% and auxiliary material 0-10%. The isolation layer comprises the following raw materials in percentage by mass: film-forming material 70-100%, plasticizer 0-30% and auxiliary material 0-10%. The mononitrate isosorbide oral dissolving film prepared by the application has the advantages of smooth appearance, good taste, uniform drug content, rapid dissolution under the action of saliva after entering the mouth, and further release and absorption, which greatly improves the drug administration compliance and solves the problem of surface crystallization of mononitrate isosorbide after long-term storage.
Owner:SHANDONG QIDU PHARMA

Method for detecting related substances in isosorbide mononitrate tablet

The invention discloses a method for detecting a related substance in an isosorbide mononitrate tablet, which comprises the following steps of: detecting the related substance isosorbide acetate in the isosorbide mononitrate tablet by adopting a high performance liquid chromatography, and eluting by taking octadecylsilane chemically bonded silica as a chromatographic column of a filler, buffer salt or water as a mobile phase A and methanol as a mobile phase B; the detection wavelength is 210 to 220 nm; and the sample size is 10-50 [mu] l. By utilizing the method, the separation degrees of peaks of the related substances isosorbide acetate and isosorbide mononitrate both reach 2.0 or above, and the recovery rates of impurities both meet the requirements of 80.0%-120.0%; the method has the advantages of high specificity and high sensitivity, and realizes better quality control of the isosorbide mononitrate tablets.
Owner:SHANGHAI XUDONGHAI PUJIADING PHARMACEUTICAL FACTORY

High-speed rotary tablet press for isosorbide mononitrate sustained-release capsule medicament

ActiveCN224044667UPharmaceutical product form changeShaping pressIsosorbide mononitrateDrug product
The utility model provides a high-speed rotary tablet press for isosorbide mononitrate sustained-release capsule medicaments, belongs to the technical field of pharmaceutical production, and aims to solve the problem that a rotary processing part is easy to hurt people when the rotary processing part is operated by the people at present. Comprising a tabletting main body, a tabletting rotating plate, an operation panel, an emergency stop switch, a protective rotating shaft, a shutdown pressing block, a protective plate switching mechanism and a maintenance shutdown mechanism, the tablet pressing part is arranged in the tablet pressing main body; the operation panel is fixedly connected to the right end face of the pressing piece body. The emergency stop switch is fixedly connected to the front side of the operation panel; the protective rotating shaft is rotationally connected to the interior of the pressing sheet main body; the shutdown pressing block is connected to the interior of the pressing sheet main body in a sliding manner; the protective plate switching mechanism is arranged in the tablet pressing main body; and the maintenance shutdown mechanism is arranged on the right side in the tabletting main body. By means of the protection plate opening and closing mechanism, personnel can maintain the tablet pressing part conveniently, and by means of the maintenance stopping mechanism, the safety of the personnel for maintaining the tablet press is guaranteed.
Owner:HUAYU WU XI PHARMA

Sustained-release capsule of isosorbide mononitrate and its preparation method

ActiveCN116650445BMicrocapsulesCardiovascular disorderCaplet Dosage FormSustained Release Capsule
The present application provides a kind of isosorbide mononitrate sustained-release capsules and its preparation method, the isosorbide mononitrate sustained-release capsule of the present application, characterized in that, the drug loading layer, sustained-release layer, immediate-release layer and protective layer of the isosorbide mononitrate sustained-release capsule are respectively coated by fluidized bed granulation coating machine.The granular preparation has good stability, small side effect;The preparation process of the isosorbide mononitrate sustained-release capsule of the present application is simple, the equipment is simple and easy to operate, the labor intensity is small, and it is economic and safe.At the same time, the prescription and preparation method are more economical, and are suitable for industrial production.
Owner:SHANDONG NEW TIME PHARMA CO LTD

L-alanine crystal and method for producing the same

ActiveCN117586139BCrystallization conditions screeningOrganic compound preparationMedicineBiochemistry
The application discloses L-alanine crystals and a preparation method thereof, relates to the technical field of L-alanine crystal preparation, and is characterized in that a morphology regulator is added into an aqueous solution containing L-alanine, crystallization is performed, and L-alanine crystals are obtained; the morphology regulator comprises any one or a combination of more than one of paclitaxel, isosorbide mononitrate and lactic acid. In the application, the morphology regulator is added into the aqueous solution containing L-alanine, the growth of the long axis of the crystals is inhibited, the growth of the short axis is promoted, and short rod-shaped L-alanine crystals are obtained. The application has the advantages of simple process, easy control and environmental protection.
Owner:TIANJIN UNIV +1

Application of coating premix in isosorbide mononitrate tablet and isosorbide mononitrate tablet

The invention relates to an application of a coating premix in an isosorbide mononitrate tablet and the isosorbide mononitrate tablet. The coating premix is prepared from the following components in parts by weight: 40 to 60 parts of eudragit RS100, 20 to 30 parts of eudragit RL100, 10 to 15 parts of plasticizer, 15 to 20 parts of coloring agent, 15 to 20 parts of anti-sticking agent and 500 to 600 parts of solvent; the eudragit RS100 is prepared from ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamine ethyl ester; the eudragit RL100 is prepared from ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamine ethyl ester; through the application of the coating premix in the isosorbide mononitrate tablet, the technical problems that the existing isosorbide mononitrate tablet cannot be disintegrated and released after reaching the ileocecum of a human body, and the bioavailability of the medicine cannot be ensured are solved.
Owner:NETANYA (BEIJING) HEALTH TECH DEV CO LTD